Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT03074513
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Appendix Adenocarcinoma
  • Human Papillomavirus-Related Anal Squamous Cell Carcinoma
  • Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
  • Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
  • Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
  • Neuroendocrine Carcinoma
  • Pancreatic Neuroendocrine Tumor
  • Recurrent Merkel Cell Carcinoma
  • Recurrent Nasopharynx Carcinoma
  • Recurrent Peritoneal Malignant Mesothelioma
  • Recurrent Pleural Malignant Mesothelioma
  • Stage III Merkel Cell Carcinoma AJCC v7
  • Stage III Nasopharyngeal Carcinoma AJCC v7
  • Stage III Pleural Malignant Mesothelioma AJCC v7
  • Stage IV Merkel Cell Carcinoma AJCC v7
  • Stage IV Nasopharyngeal Carcinoma AJCC v7
  • Stage IV Pleural Malignant Mesothelioma AJCC v7
  • Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • Stage IVB Nasopharyngeal Carcinoma AJCC v7
  • Stage IVC Nasopharyngeal Carcinoma AJCC v7
  • Vaginal Squamous Cell Carcinoma, Not Otherwise Specified

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Given IV
  • Bevacizumab — BIOLOGICAL
    Given IV
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Pharmacological Study — OTHER
    Correlative studies

Study Details

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date
Mar 3, 2017
Status verified
Mar 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
133 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (atezolizumab, bevacizumab)
    Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Objective response [ Time Frame: Up to 4 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
M D Anderson Cancer Center· Houston, TX

Related Studies